Adage Capital Partners Gp, L.L.C. Theravance Biopharma, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$14.89 - $20.16 $10.4 Million - $14.1 Million	-700,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$14.79 - $22.49 $4.07 Million - $6.18 Million	-275,000 Reduced 28.21%	700,000 $10.4 Million
Q2 2020 Aug 14, 2020	BUY	$20.64 - $30.69 $4.13 Million - $6.14 Million	200,000 Added 25.81%	975,000 $20.5 Million
Q1 2020 May 15, 2020	BUY	$17.84 - $31.21 $13.8 Million - $24.2 Million	775,000 New	775,000 $17.9 Million

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $618M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.